Biotechnology company Ionis Pharmaceuticals Inc (Nasdaq:IONS) announced on Tuesday that it has entered into an expanded licensing agreement with Japan's Otsuka Pharmaceutical Co Ltd for donidalorsen, an investigational RNA-targeted therapy for hereditary angioedema (HAE).
Otsuka gains exclusive commercialisation rights in the Asia-Pacific region, adding to its commercialisation rights in Europe. Ionis retains responsibility for global development and plans a US Food and Drug Administration (FDA) filing this year for independent launch in the United States.
The agreement includes a USD20m upfront payment to Ionis with potential milestone and royalty payments tied to regulatory and sales achievements.
Otsuka's regional expertise and infrastructure aim to deliver donidalorsen to HAE patients across Asia-Pacific.
DATROWAY receives US priority review for first-line metastatic triple negative breast cancer
Lupin launches Dasatinib tablets in US market
Natera submits Signatera CDx PMA to FDA for bladder cancer use
Pharming receives FDA complete response letter for paediatric Joenja application
Trace Biosciences' IND application for nerve-specific imaging agent approved by FDA
Frontage expands early phase clinical research capabilities across US and China
MicuRx Pharmaceuticals' IND application for MRX-5 cleared by FDA
FDA approves Tenpoint Therapeutics' YUVEZZI as first dual-agent eye drop for presbyopia
Summit Therapeutics' BLA for ivonescimab in EGFR-mutated NSCLC accepted by FDA
WuXi Biologics collaborates with Sinorda Biomedicine for antibody development
Biogen's litifilimab receives FDA Breakthrough Therapy Designation for CLE
Glaukos receives FDA approval for repeat administration of iDose TR
Guerbet's contrast agent Elucirem approved by European Commission in children from birth
Spine Innovation's LOGIC Titanium Implant System receives US FDA 510(k) market approval